Patients with inflammatory bowel disease (IBD) show high acceptance of adalimumab biosimilars, achieving positive outcomes and clinical remission after switching.

In an interview, James D. Chambers, Ph.D., from Tufts Medical Center, talks about the factors that are impacting the ...

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

New research highlights the efficacy and high patient satisfaction of adalimumab biosimilars in treating inflammatory ...

Switching to Humira biosimilars saved Navitus clients more than $315 million in upfront costs in 2024 and resulted in a 60% ...